Sandoz announced that it has launched a generic paclitaxel formulation in the U.S., the first generic to its reference medicine to be approved by the FDA.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SDZNY:
- Sandoz downgraded to Sector Perform from Outperform at RBC Capital
- Sandoz downgraded to Hold from Buy at Berenberg
- Sandoz price target raised to CHF 33 from CHF 28 at Deutsche Bank
- Axsome Therapeutics reaches agreement to dismiss patent litigation with Sandoz
- Sandoz Canada announces launch of Jubbonti, Wyost